- Dan Chamby Joins CMTA Board of Directors
The CMTA, the national patient advocacy organization leading CMT research, today announced the appointment of Dan Chamby to its Board of DirectorsRead more ... - New, Potentially Treatable, Type of CMT Discovered A team led by Dr. Stephan Züchner at the University of Miami has discovered a new type of Charcot-Marie-Tooth (CMT) disease that may be treatable with drugs already approved for other diseases.Read more ...
- CMT2E Gene Therapy Project Approved The CMTA Board of Directors approved a $265,000 research project for CMT2E that aims to advance CMT2E gene therapy by demonstrating positive results for axonal forms of CMT affecting motor neurons.Read more ...
- The 2020 Spring CMTA Report In a world turned upside down, The CMTA Report continues to bring you help for today and hope for tomorrow. In this issue you’ll find helpful stories on tendon transfers, HNPP and nerve conduction studies, as well as hopeful news ...Read more ...
- CMTA Board Approves CMT1B Project The CMTA Board of Directors approved a new research project aimed at developing biomarkers for CMT1B to aid in the collection of natural history data critical to clinical trials.Read more ...
When you participate in the Walk 4 CMT campaign, you fund patient programs and treatment research initiatives to better the lives of the the 3 million people living with CMT.
By investing in the CMTA’s Legacy Society, you can ensure that children with CMT will grow up with the hope of a world without CMT.
